Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation.

[1]  J. Hallas,et al.  External validity of a cardiovascular screening including a coronary artery calcium examination in middle-aged individuals from the general population , 2018, European journal of preventive cardiology.

[2]  G. Parati,et al.  Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long‐term comparison , 2017, European journal of heart failure.

[3]  A. Rigby,et al.  Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials , 2018, European heart journal.

[4]  G. Parati,et al.  Prognostic role of β‐blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database , 2017, European journal of heart failure.

[5]  A. Rigby,et al.  Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. , 2017, Journal of the American College of Cardiology.

[6]  L. Allen,et al.  Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet. , 2017, JACC. Heart failure.

[7]  J. Andrade,et al.  Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. , 2017, JACC. Heart failure.

[8]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[9]  Yang Zhang,et al.  Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study , 2016, European journal of preventive cardiology.

[10]  G. Parati,et al.  Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. , 2015, European journal of internal medicine.

[11]  P. Kirchhof,et al.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis , 2014, The Lancet.

[12]  J. Piccini,et al.  Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. , 2014, Journal of the American College of Cardiology.

[13]  L. Køber,et al.  Comparison of the clinical outcome of different beta‐blockers in heart failure patients: a retrospective nationwide cohort study , 2014, European journal of heart failure.

[14]  A. Iorio,et al.  Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial. , 2013, International journal of cardiology.

[15]  G. Parati,et al.  Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. , 2013, International journal of cardiology.

[16]  I. V. Van Gelder,et al.  Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. , 2013, JACC. Heart failure.

[17]  W. Kraus,et al.  Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. , 2012, Journal of the American College of Cardiology.

[18]  P. Agostoni,et al.  Effects of beta-blockers on ventilation efficiency in heart failure. , 2010, American heart journal.

[19]  M. Mamas,et al.  A meta‐analysis of the prognostic significance of atrial fibrillation in chronic heart failure , 2009, European journal of heart failure.

[20]  Natasha Wiebe,et al.  Meta-analysis: -Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure , 2009, Annals of Internal Medicine.

[21]  A. Capucci,et al.  Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[22]  M. Emdin,et al.  Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. , 2008, European heart journal.

[23]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[24]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[25]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[26]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[27]  Crijns,et al.  Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. , 1994, British heart journal.

[28]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[29]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.